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Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour in adults.
Treatments include surgical resection, radiotherapy, and chemotherapy. Despite this, the prognosis
remains poor, with an impacted quality of life during treatment coupled with brain tumour recurrence;
thus, new treatments are desperately needed. In this review, we focus on recent advances in G-protein-
coupled receptor (GPCR) targets. To date, the most promising targets are the chemokine, cannabinoid,
and dopamine receptors, but future work should further examine the melanocortin receptor-4 (MC4R),
adhesion, lysophosphatidic acid (LPA) and smoothened (Smo) receptors to initiate new drug-screening
strategies and targeted delivery of safe and effective GBM therapies.
Keywords: G-protein-coupled receptors (GPCRs); Glioblastoma multiforme (GBM)
Introduction
Tumours involving glial cells, or gliomas, are the most common
tumours of the central nervous system (CNS) and comprise two
subgroups; diffuse gliomas and nondiffuse gliomas.1 Diffuse infil-
trating gliomas (diffuse IGs) account for 80% of primary malig-
nant gliomas and are histopathologically classified as
astrocytoma isocitrate dehydrogenase (IDH)-mutant, astrocy-
toma IDH-wild-type, and oligodendroglioma.2,3 IDH1 and
IDH2 are key enzymes involved in cellular metabolism, epige-
netic regulation, redox states. and DNA repair.4 Genes that
encode IDH1 and IDH2 are frequently mutated in multiple types
of cancer, whereby ~ 90% of mutations are of the IDH1 type.2,5
Examples of such cancers include acute myeloid leukemia
(AML), myeloid malignancies, and gliomas.6 The molecular clas-
sification of an oligodendroglioma is such that it has complete
chromosome 1p and 19q co-deletion. Oligodendrogliomas
account for < 10% of diffuse gliomas.7
The glioma tumour grading system of the WHO ranges from
grade I to grade IV,8 assigned based on pathological features,
such as vascular proliferation, mitotic activity, necrosis, and pro-
liferative potential.9 GBM is an example of a grade IV tumour
because it is a more advanced tumour with more malignant fea-
tures, including vascular proliferation and necrosis.10 According
to the Central Brain Tumour Registry of the USA (CBTRUS),
GBM is the most commonly occurring primary malignant brain
and CNS tumour, accounting for 14.5% of all CNS tumours and
48.6% of all malignant tumours.11 The median survival rate for
patients with GBM is 8 months.11
GBMs are classified as either IDH wild-type or IDH mutant.
IDH-wild-type GBMs develop quickly and are molecularly dis-
tinct from the IDH-mutant type, which usually results from a
lower grade glioma. IDH-mutant GBMs are primarily observed
in younger patients, with a median age of 45 years, and has a bet-
ter prognosis compared with IDH wild-type, where the median
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age is 60 years.1,3,12 The IDH-wild-type form accounts for 90% of
GBMs and, consequently, has more related research performed.12
Current therapeutic strategies in glioblastoma
Patients with brain tumours can present a variety of general
symptoms, the most common include increased intracranial
pressure (ICP), seizures, headache, fatigue, nausea, and vomiting,
as well as cognitive dysfunction.13 Patients with GBM have a
median survival rate of 3–4 months without treatment, whereas
the median survival rate for patients who receive treatment
increases to 15 months.14
Current therapeutic strategies to treat GBM include surgical
resection followed by radiotherapy and chemotherapy, which
are referred to as the ‘Stupp Protocol’.15 Initial surgery remains
a hallmark in the treatment of malignant brain tumours.16 How-
ever, because of the invasive nature of GBM, there are cells that
remain after surgery that contribute to tumour recurrence.16
The success of cancer chemotherapy depends on the develop-
ment of drugs that selectively destroy tumour cells or limit their
proliferation without causing severe adverse effects.17 Drug treat-
ment in neurological diseases, such as brain tumours, are partic-
ularly difficult because of the protective CNS barrier, which
comprises the blood–brain barrier (BBB) and the blood–cere-
brospinal fluid barrier (BCSFB). Many approved anticancer drugs
do not readily cross the BBB, thus limiting the options for GBM
treatment.18
The most used chemotherapeutic agents for the treatment of
GBM are bevacizumab, sunitinib, lomustine (CCNU), procar-
bazine, carmustine (BCNU) and the gold standard, temozolo-
mide (TMZ).16,19
Temozolomide
TMZ is the most frequently used chemotherapeutic agent for
GBM treatment and has increased the patient median survival
rate from 12.1 months to 14.6 months.19 The percentage of
patients alive at 2 years also increased from 10.4% to 26.5%.19
TMZ belongs to a class of second-generation imidazotetrazine
prodrugs, which were developed during the 1980s.20 Given its
small size (194 Da), stability at acidic pH, and lipophilic proper-
ties, TMZ can cross the BBB (Fig. 1).20,19
However, prolonged TMZ treatment leads to resistance and a
poor response to subsequent treatments.20 It also requires con-
tinuous administration because of its low solubility in physiolog-
ical media and shorter plasma half-life (1.8 h). The dosage of
TMZ delivered is 150–200 mg/m2 for 5 days every 28 days for
six cycles.21 Although higher doses of TMZ allow for positive out-
comes, such as tumour death, there are negative effects associ-
ated, such as cardiomyopathy, haematological toxicity, and
pneumonia, which can result in the cessation of treatment.22
The limitations associated with TMZ therapy have resulted in
TMZ being used in conjunction with other therapeutics in a
bid to improve its efficacy.23
Other chemotherapeutic agents for GBM
Sunitinib (Fig. 1) is an oral multi-targeted tyrosine kinase inhibi-
tor that is used in the treatment of metastatic renal cell carci-
noma and that has shown potential in the treatment of
GBM.24 To date, sunitinib has been part of a Phase II trial (Clin-
icalTrials.gov ID: NCT03025893) in conjunction with lomustine
in patients with recurrent GBM.25 Lomustine and procarbazine
are both orally administered alkylating agents and can be used
as a stand-alone treatment for GBM or in conjunction with
TMZ.26
Carmustine wafers (CWs) are a form of the medication car-
mustine (BCNU) and are used in the treatment of recurrent
GBM as an adjunct to surgery.27 CWs are recommended for
patients for whom near-total surgical resection is feasible or in
whom craniotomy is indicated.28 The success of CWs has led
to the development of TMZ delivery through a polymer wafer,
which can be used as an alternate or complimentary treatment.29
Preclinical studies were carried out using CWs, TMZ wafers, and
wafers that were coloaded with both BCNU and TMZ against an
Drug Discovery Today
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intracranial 9L gliosarcoma model in F344 rats. Rats that received
the TMZ wafer had a higher survival rate (18 days) over rats that
received the CWs (15 days), whereas rats that received the BCNU-
TMZ wafer had the highest overall survival rate (28 days), with
25% of them living long term. Despite this success of the
BCNU-TMZ combination, it has not been delivered on a
coloaded wafer successfully in a clinical setting. Nevertheless,
this research can be used to improve local drug delivery and
increase therapeutic options for patients with GBM.29
Bevacizumab is a humanised monoclonal antibody against
vascular endothelial growth factor A (VEGF-A) and is used in
the treatment of several different cancers, including cervical, col-
orectal and GBM.30 It is used as a last in-line treatment for GBM
following the failure of radiotherapy, lomustine, and TMZ.31
Search for novel protein targets for GBM
Most drug targets are in one of five protein families: GPCRs, ion
channels, kinases, nuclear hormone receptors, and proteases.32
GPCRs are considered one of the most important classes of phar-
macological targets because they can act as both primary and sec-
ondary targets.33 They also regulate numerous physiological
processes, such as cell signalling and cell communication, as well
as having druggable sites accessible at the cell surface.34 It is esti-
mated that 27% of all US Food and Drug Administration (FDA)-
approved therapeutics that are sold target 108 GPCRs.32
Recently, GPCRs have become an emerging oncogenic target
class for GBM.
G-protein-coupled receptors
GPCRs comprise the largest family of membrane proteins, which
include more than 800 members in humans.32 Structurally,
GPCRs share a core of seven transmembrane (TM) a-helices, an
extracellular N terminus, and an intracellular C terminus, with
various extracellular and intracellular loops.35 Functionally,
GPCRs regulate activities of intracellular signalling via G proteins
and b-arrestin (Fig. 2).35 Upon GPCR activation, G-proteins/b-
arrestins translocate to the cell membrane, where they bind to
the agonist-occupied receptors, triggering a variety of physiolog-
ical responses, such as neurotransmission, metabolism, cell dif-
ferentiation, inflammatory, and immune response, as well as
vision, taste, and olfaction.36
Drug Discovery Today
FIGURE 2
Schematic of diverse signalling pathways of G-protein-coupled receptors triggered upon activation of G-protein subunits (a, b and c). Agonist-bound GPCR
exchanges GDP for GTP on the Ga subunit, thus triggering Ga (s, i, q, 12) dissociation from the receptor and Gbc. (a) Activated Gas stimulates membrane-
associated enzyme adenylyl cyclase (AC), which increases ATP–cAMP conversion. cAMP acts as a second messenger to activate protein kinase A (PKA), which
can phosphorylate multiple downstream targets; whereas Gai subunit inhibits AC. (b) Activated Gaq stimulates the membrane-bound phospholipase C (PLC)
to cleave phosphatidylinositol biphosphate (PIP2) into the second messengers inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 increases intracellular
calcium concentrations (Ca2+), whereas membrane-bound DAG activates PKC by translocating it from the cytosol to the plasma membrane. GPCR kinase
(GRK) phosphorylates G-protein-independent ligand-bound GPCRs to initiate the recruitment of b-arrestin and blocks G-protein coupling. The GPCR-b–
arrestin complex promotes endocytosis, trafficking ligand–GPCRs to sorting endosomes for either recycling to plasma membrane or signalling and regulation
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A widely used classification system for GPCRs, referred to as
the A-F system (Table 1), separated the GPCRs into six classes
based on their amino acid sequences and their functional simi-
larities for both vertebrates and invertebrates.36 Class A is the lar-
gest family, accounting for ~ 80% of GPCRs, and is referred to as
the ‘rhodopsin-like family’. Class B contains 70 receptors and is
referred to as the ‘secretin receptor family’. Class C examples
include the glutamate family, GABA receptors, and calcium-
sensing receptors. Class D includes fungal mating pheromone
receptors; Class E contains cAMP receptors, and Class F contains
frizzled/smoothened receptors.36 A new classification system was
subsequently devised referred to as the ‘GRAFS’ system
(Table 1),36,37 based on structural similarity and the phylogenetic
tree of ~ 800 human genome sequences.37 This system comprises
five families: Glutamate (G), Rhodopsin (R), Adhesion (A), Friz-
zled/Taste2 (F), and Secretion (S).36 A variety of GPCR family
members are considered as potential GBM targets, and the
remainder of this review focuses on GPCRs expressed on GBM
cells.
Rhodopsin type GPCRs and GBM
Chemokine receptors
Chemokine receptors are classified as typical (GPCRs) and atypi-
cal chemokine receptors (ACKRs).38 ACKRs are cell surface recep-
tors with seven TM domains and are structurally homologous to
chemokine GPCRs; however they fail to induce classical sig-
nalling and cellular responses, which are characteristic of GPCRs.
Nevertheless, ACKRs are important in terms of health and dis-
ease.39 CXCR4 is an example of a typical chemokine receptor,
whereas CXCR7 is an atypical receptor.40 Along with their
CXCL12 ligand (stromal derived factor 1/SDF-1 ligand), these
are the most widely studied chemokine systems involved in
tumour growth, metastasis, and angiogenesis.41 CXCR4 and
CXCL12 are upregulated in brain cancers, such as meningiomas
and GBM.42 The significance of CXCL4/CXCR12 expression and
function has been studied in both children and adults with
GBM.42 CXCR4 expression corresponds to tumour grade and it
is overexpressed in GBM stem cells (GSCs), which drives GBM
progression.43 CXCR4 expression is observed in hypoxic areas
of the tumour.43 In addition, hypoxia enhances CXCL12 secre-
tion, thus driving angiogenesis and feeding tumour develop-
ment.42 This is also observed when GBM is treated with
radiation because this triggers upregulation of hypoxia-
inducible factor 1a (HIF-1a) and CXCR4.42,43 Therefore, a CXCR4
antagonist preventing this protein–protein interaction, between
CXCR4 and CXCR12, could be a valuable therapeutic in the
treatment of GBM. Both in vitro and in vivo studies using CXCR4
antagonists in combination with current GBM treatment have
also been pursued.43
A study of the CXCR4 antagonist plerixafor (Fig. 3) showed
that tumour recurrence was prevented in orthotopic xenografts
of GBM in a mouse model. Plerixafor selectively inhibits CXCL12
binding to CXCR4 as well as inhibiting CXCL12-mediated
chemotaxis.44 In the 3-week in vivo study, the GBM tumours con-
tinued to shrink and did not recur even when exposure to plerix-
afor ceased.44,45
From this experimental model, the dose and schedule of
administration of plerixafor was used in an adjuvant treatment
study of a 66-year-old patient with GBM.45 The patient was trea-
ted after chemoradiotherapy, receiving a total of 60 Gray (Gy) in
30 fractions with a concurrent dose of TMZ. The patient was
then treated with plerixafor and a combination of a mammalian
target of rapamycin (mTOR), a sirtuin 1 (SIRT1), and an epider-
mal growth factor receptor variant III (EGFRvIII) inhibitor. After
1 year of treatment, the use of TMZ and the EGFRvIII inhibitor
was stopped, whereas the plerixafor and mTOR and SIRT1 inhi-
bitors were continued. The patient was in remission at
30 months from the initiation of the adjuvant treatment, high-
lighting the potential of plerixafor as an adjuvant treatment for
GBM.45
TABLE 1
GPCR Glutamate, Rhodopsin, Adhesion, Frizzled, Secretin (GRAFS) classification with characteristics, biological roles, and





Characteristics Biological roles Representative examples
Glutamate
(Class C); 22
Presence of nine conserved cysteine residues known
as cysteine-rich domain (CRD) or NCD3G in N-
terminal region
Neurobiological roles, gustatory roles






Presence of D/ERY in TM3, NPxxY in TM7, and
disulfide bond(s)
Olfactory and vision stimuli,
neurotransmitter signalling, cardiovascular






Long N termini containing multiple functional
domains and numerous sites for glycosylation







Characterised by presence of ten conserved cysteine
residues known as FZ_CRD domain or FZ domain
between N-terminal and TM regions
Developmental biology, cancer
development, perception of bitter taste;
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A Phase I/II clinical trial was performed in 2013 (ClinicalTri-
als.gov ID: NCT01977677) in which the use of plerixafor and
TMZ after radiation therapy was studied in patients with newly
diagnosed high-grade glioma to determine the optimum treat-
ment dosage.46 The hypothesis was that the recovery of the
tumour was driven by CXCL12 secretion and, thus, blocking
the CXCL12–CXCR4 axis would stop tumour recurrence. A total
of 29 patients completed the study with a recommended dose of
16.6 mg/kg/hr of plerixafor with no deleterious effects observed;
seven out of nine patients were alive at the end of the study, with
the longest survival since diagnosis being 18 months.46
A novel antagonist of CXCR4, PRX177561 (structure not
available because of commercial sensitivity) was used in conjunc-
tion with bevacizumab and sunitinib to determine its antitu-
mour activity in a mouse GBM xenograft model.47 A panel of
12 human GBM cells lines and five patient-derived GBM stem
cell cultures were used. PRX177561 alone inhibited tumour
growth and increased the efficacy of both bevacizumab and suni-
tinib, resulting in a significant reduction in tumour growth in
animal models of GBM. PRX177561 also enhanced survival in
combination with both bevacizumab and sunitinib in the animal
model. After 35 days, all treatment was stopped, and the animals
were checked for overall survival determination. The use of
CXCL12–CXCR4 targeted, combined therapy allowed for a clin-
ical trial (ClinicalTrials.gov ID: NCT02765165), which was termi-
nated for business reasons rather than concerns related to
safety.47
The therapeutic drug, fingolimod, has been proposed as a
therapeutic option for the treatment of GBM because of its abil-
ity to cross the BBB, its lipophilicity, and its ability to accumulate
in CSF. Fingolimod is a structural analogue of sphingosine 1-
phosphate (S1P) and acts as an agonist of S1P receptors,48
inhibiting the CXCR4 receptor and its ligand S1P. Cancers, such
as primary brain tumours, produce and secrete more S1P, which
has been shown to establish premetastatic niches in organs, such
as the brain, through mechanisms involving S1PR1.48 Fin-
golimod inhibited S1P signalling in multiple myeloma and it
was revealed that metastasis to the bone marrow was due to
involvement of the CXCR4–CXCL12 pathway.
Metastasis specific to the brain has not yet been studied with
respect to S1P; however, the expression of CXCL12 is positively
correlated with brain metastasis in solid tumours.49 In vitro, fin-
golimod has shown the ability to induce apoptosis in multiple
GBM cell lines as well as inhibiting migration and invasion
through the modulation of matrix metalloproteinases. It is sensi-
tive to two GBM cell lines, U87 and U-251 MG, and induces
autophagy and apoptosis in U251-MG cells in response to
TMZ.48 According to the American Type Culture Collection
(ATCC), the origins of the U87 and U-251 MG cell lines used
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line. However, these cell lines are genuine human GBM of an
unknown origin.50 A further study treated glioma-bearing Wistar
rats with fingolimod for a period of 14 days. Fingolimod inhib-
ited the growth, migration, and invasion of glioma by inhibiting
the CXCR4–CXCL12 pathway in these rats.51
CXCR7, or atypical chemokine receptor 3 (ACKR3), has a ten-
fold higher affinity for CXCL12 than for CXCR4.42 The expres-
sion of CXCR7 increases with the increasing malignancy of
tumours. CXCR7 is expressed in GBM cells and facilitates the
binding of CXCL12 to endothelial cells during hypoxia.52
An experimental model was carried out in which 24 6-week-
old mice were injected intracranially with U251-MG human
GBM cells. After a 3-week period of tumour establishment, the
mice were given whole-brain irradiation and then injected sub-
cutaneously with the CXCR7 inhibitor, CCX771. The results
showed that inhibition of CXCR7 by CCX771 post irradiation
blocked tumour recurrence and prolonged survival.53 This sug-
gests CXCR7 antagonists as a potential route to decrease the
spread of tumour cells, their metastasis, and angiogenesis.
Therefore, by inhibiting the interaction between CXCR4 and/
or CXCR7 and the ligand CXCL12, potential therapeutics to tar-
get GBM treatment and GBM recurrence could be developed.
Cannabinoid receptors
The endocannabinoid system (ECS) is an important neuromodu-
latory system comprising cannabinoid receptors, endogenous
cannabinoids (endocannabinoids), and enzymes, which are
responsible for the synthesis and degradation of endocannabi-
noids.54 Cannabinoids and endocannabinoids have a variety of
pharmacological effects. Cannabinoids are currently used in
the palliative therapy of patients with cancer, in particular
tetrahydrocannabinol (THC) or cannabidiol (CBD).55 These sub-
stances inhibit nausea and vomiting, stimulate appetite, and
reduce weight loss. Cannabinoids also affect cell proliferation,
viability, and invasiveness of cancer cells in culture and in vivo.55
The two rhodopsin-type GPCRs primarily expressed in the
human body are cannabinoid receptor type 1 (CB1) and 2
(CB2).56 The identification of CB1 and CB2 led to the isolation
and characterisation of endocannabinoids for these proteins,
namely, anandamide (AEA) (Fig. 3) and 2-arachidonoylglycerol
(2AG).57
CB1 receptors are expressed more abundantly in the body
than other GPCRs and are found in high levels in the CNS, pri-
marily on the preterminal axonal segment and the axons them-
selves.54 They are also found in regions of the brain responsible
for motor activity, memory, and cognition.55 CB2 receptors are
primarily expressed on immune cells, such as those derived from
macrophages (e.g., microglia, osteoblasts, and osteoclasts).54,56
CB2 receptors are also responsible for the anti-inflammatory
effects of endocannabinoids.56 Both CB1 and CB2 receptors sig-
nal through the inhibitory G-alpha proteins Gi and Go.
56
The expression of CB1 and CB2 receptors is altered in tumour
types, such as brain, digestive tract, breast and prostate tumours,
and has been related to cancer prognosis in GBM tumours
expressing both CB1 and CB2 receptors.58 There are high levels
of CB2 receptors expressed in high-grade gliomas, such as
GBM, and this expression positively correlates with the malig-
nancy grade. CB1 receptor expression still requires characterisa-
tion because it has been reported to be increased, decreased, or
unchanged in GBM compared with low-grade gliomas or nontu-
mour control tissues.58
Cannabinoids and endocannabinoids can directly inhibit
tumour growth in vitro in cancers such as GBM by inducing
apoptosis, reducing tumour growth, and inhibiting neo-
angiogenesis.59 In addition, hypoxia-induced inhibition of the
endocannabinoid system aids the development of GBM.
Hypoxia decreases the levels of CB1 and the astrocyte fibrillary
acidic protein, and increases the levels of the enzyme responsible
for the metabolism of endocannabinoids, VEGF, and
cyclooxygenase-2 (COX-2). Cannabinoid receptor engagement
induces cell death in GBM U-87 cells in normoxic conditions
and cannabinoid receptor agonist cell death was associated with
hypoxic conditions.60
The effects of the synthetic agonists CP55-940 and WIN
55,212–2 (Fig. 3) on cannabinoid receptors were first demon-
strated during the 1990’s when antinociceptive activity was dis-
played in mouse and rat tail flick tests.61 A study by Ortega et al.,
in which synthetic CB1 agonists CP55-940 andWIN 55,212–2, as
well as the endogenous CB1 agonist, anandamide (AEA) (Fig. 3)
were compared in terms of morphological changes, cell viability,
and induction of apoptosis in primary astrocytes and two GBM
cell lines, C6 and U251-MG. The study was performed to charac-
terise the possible differential actions on brain tumour cells.62
None of the CB1 agonists induced any changes in cell morphol-
ogy or cell viability in primary astrocytes. By comparison, CP55-
940 decreased cell viability in both GBM cell lines after 5 days of
treatment, whereas WIN 55,212–2 and AEA only moderately
decreased cell viability in both cell lines. Discrete morphological
changes in U251 and C6 cells resulted from treatment with AEA
and WIN 55–212- 2, whereas exposure to CP55-940 induced
some degradation. CP55-940 also induced apoptosis in both C6
and U251-MG cell lines. This study proposed that apoptosis is
the major mechanism contributing to cannabinoid-induced
death of cancer cells.62 The work also highlighted the need to
compare effects of cannabinoids to design potential treatments
against glial tumours.
To date, most studies have focussed on agonistic stimulation
via CB receptors, stating that this is responsible for the antitu-
mour effects of cannabinoids.63 However, a study by Ciaglia
et al. suggests that CB1 antagonists would also be useful in
glioma therapy.63,64 Pharmacological inactivation of CB1 by
rimonabant (Fig. 3) inhibited glioma cell growth of the U251-
MG cell line via cell cycle arrest and induction of caspase-
dependent apoptosis. Rimonabant-induced MICA/B upregula-
tion also directly correlated with the degree of CB1 expression
and occurred in malignant glioma cells but not in normal human
astrocytes.64 As such, the use of CB1 antagonists could be
explored further in animal studies as potential therapeutics for
certain subsets of GBM with high CB1 expression levels.
An in vivo study was carried out on primary human GBM and
anaplastic astrocytoma cells using a novel cannabinoid CB2 ago-
nist, COR167. The CB2 agonist was found to inhibit the growth
of the cells in vitro by a mechanism independent of apoptosis.
These findings suggest that a role for the selective CB2 receptor
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should be carried out to explore in vivo models of this CB2
agonist.65
Another challenge in treating GBM is the presence of GSCs,
which express both cannabinoid receptors CB1 and CB2. The
cannabinoids were shown to reduce the efficacy of GSCs to initi-
ate glioma formation in vivo and was indicated by decreased cell
proliferation.58 Therefore, cannabinoid signalling has a role in
inhibiting tumorigenesis and could have a role in the treatment
of GBM.43
Dopamine receptors
There are five dopamine receptors (DR), D1–D5, which are mem-
bers of the Rhodopsin subfamily and are responsible for the
actions of the neurotransmitter, dopamine. The dopaminergic
system controls brain functions, such as motor control, beha-
viour, and cognition, and is targeted by multiple therapeutically
active drugs as well as drugs of abuse.66 DRD2 has been the most
extensively studied in cancer, and is overexpressed in high-grade
gliomas, such as GBM. ONC201 (Fig. 3) was the first small-
molecule DRD2 antagonist for oncology to demonstrate p53-
independent antitumour activity in preclinical models of GBM
and several other cancers. The compound crosses the BBB in
rodents and exhibited antiglioma activity in an orthotopic
model of GBM.67 Currently, ONC201 is in an active Phase II trial
(ClinicalTrial.gov ID: NCT02525692) to be used as treatment in
recurrent GBM or recurrent Grade IV gliomas with a H3 K27M
mutation.67
Neurokinin 1 receptor
Neurokinin 1 receptor (NK-1) is the most studied tachykinin
receptor and belongs to the Rhodopsin family of GPCRs.43,68
The NK-1 receptor occurs in the nervous system and peripheral
tissues.68 It is also involved in cellular responses, such as pain
transmission, vasodilation, and modulation of cell prolifera-
tion.68 Substance P (SP) is a neuropeptide and the major endoge-
nous ligand for the NK-1 receptor.69,70 The number of NK-1
receptors expressed on tumour cells is greater than that expressed
on normal cells and so is correlated directly with the malig-
nancy.69 Overexpression of the NK-1 receptor was found in
100% (10/10 cases) of GBM biopsy specimens studied.70
Aprepitant (Fig. 4) is the only NK-1 receptor antagonist drug
with FDA approval and is used as a post-chemotherapy antie-
metic drug.71,72 Aprepitant and marketed nonchemotherapy
drugs were tested on the glioma cell line, GAMG, to establish
whether they had an ability to enhance the cytotoxicity of
TMZ.72 Four antiviral drugs were tested, acyclovir, cidofovir, mar-
aviroc, and ritonavir, as well as Aprepitant and TMZ. No toxicity
was found for acyclovir, cidofovir and maraviroc, whereas cyto-
toxicity for GAMG alone for both TMZ and ritonavir was 14%
and aprepitant alone was 7%. However, the cytotoxicity value
for all three drugs was 78%. This study concluded that both
ritonavir and aprepitant should be added to the Stupp protocol
because of the observed increased cytotoxicity.72
Melanocortin receptor-4
Melanocortins are peptides with anti-inflammatory and neuro-
protective activity. There are five melanocortin receptors (MCRs;
MC1–5R), with only MC4R being present in astrocytes and,
hence, is referred to as a neural MCR.73 Vaglini et al. evaluated
the presence of MC4Rs in GBM cells and the selective inhibition
of their activity through the MC4R antagonist, ML00253764,
alone and in combination with TMZ in vitro and in vivo. In vitro
studies were carried out on human GBM cells (U-87 and U-118)
and in vivo studies were carried out on nude xenografted mice.
The simultaneous combination of TMZ and ML00253764 deter-
mined a highly synergistic effect on GBM cells. The same combi-
nation in vivo showed a strong and significant decrease in GBM
tumour volumes.74 A Phase III clinical trial was also carried out
(ClinicalTrial.gov ID: NCT02458508) to evaluate the possible
predictive/prognostic role of MC4R in patients with GBM. There
is currently no description of MC4R expression or activity in
human cancer cells, including GBM, or their relationship with
radiotherapy and chemotherapy, hence the aim of the study.75
The study showed that the MC4R rs489693 genotype homozy-
gous for allele A was associated with a significantly shorter
progression-free survival and overall survival in patients treated







13. Structure of Neurokinin 1 receptor antagonist drug Aprepitant 14. Structure of the antiviral drug ritonavir.
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Adhesion GPCRs
Adhesion GPCRs (aGPCRs) are the second largest group in the
GPCR family and comprise 33 human receptors divided into
eight groups.76 The nomenclature for the receptors was recently
updated by the International Union of Basic and Clinical Phar-
macology and all aGCPRs now contain an ADGR prefix, followed
by a letter indicating the receptor subfamily and a number for
each receptor within that group.76 They regulate various cellular
functions in the body, such as migration, polarity, and
adhesion.77
The adhesion receptors are distinguished by their large N-
terminal regions, which can contain epidermal growth factor
(EGF), cadherin, immunoglobulin domains, and novel lineage-
specific structures. The complexity of these receptors, their size,
and the fact that they are usually tethered to other cells have
proven to be challenges in identifying and characterising
them.78
The adhesion receptor GPR133 (or ADGRD1) has been
reported to enhance tumorigenesis and is upregulated in
GBM.77 The presence of GPR133/ADGRD1 is observed in
hypoxic GBM cells, and the levels at which it is expressed corre-
late directly with patient survival.76 RNA sequencing was carried
out on a primary human GBM culture to determine which genes
were upregulated and downregulated in CD133+ cells. GPR133
was selectively expressed in the hypoxic areas of these cells and
genetic inhibition of GPR133 with short hairpin RNA reduced
the prevalence of CD133+ cell tumour proliferation and tumour
formation in vitro.79 Further studies using patient-derived cul-
tures and xenografts of GBM showed that GPR133 expression
is at its highest in GBM, suggesting that high GPR133 levels sup-
port tumour growth and are associated with a reduced patient
survival rate. As such, GPR133 represents a novel therapeutic tar-
get in GBM to be explored further.80
EGF module-containing mucin-like hormone receptor 2 and
3, EMR2 and EMR3, are both upregulated in GBM and are also
associated with poor survival.81 Both receptors have unknown
ligands and cellular function.82 In vitro analysis showed that
EMR3 has a key role in GBM migration and invasion, but no
effect on cell proliferation.83 However, EMR2 and EMR3 recep-
tors have a complex structure with no mouse orthologs and there
is limited information about their intracellular targets.84
Despite aGPCRs having been recognised as suitable targets for
therapeutics, they remain largely unexplored with no FDA
approved drugs as of late 2019.85 A greater understanding of
the mechanism of action of aGPCRs would facilitate new drug
screening strategies to treat illnesses, such as GBM, which are
linked to aGPCR dysfunction.86
Lysophospholipid receptors
Two agonistic lysophospholipids (LPLs) that have been most
characterised are LPA and S1P.87 They have a significant role as
extracellular mediators by activating GPCRs and stimulating
diverse cellular responses from their signalling pathways.88 The
effects of LPLs in a cancer microenvironment are widely studied
because these lipids are secreted by various cell types, including
cancerous cells.89 S1P and LPA have a key role in particular in
regulating the growth of tumour cells and manipulating the
immune system.89
Lysophosphatidic acid
LPA (Fig. 5) is a small glycerophospholipid molecule (430–
480 Da) that acts as an extracellular signalling molecule through
at least six class A lysophosphatidic acid GPCRs [LPA(1–6)].90
LPA is involved in the tumorigenesis of cancers, including
GBM.91 LPA receptor (LPAR) agonists and LPA synthesis inhibi-
tors have been proposed as promising drugs for cancer treatment.
Drug Discovery Today
FIGURE 5
Structure of lysophospholipid receptor ligands. 15. Lysophosphatidic acid (LPA). 16. Structure of LPA receptor inhibitor Ki6425. Structures of Smoothened
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LPA1 is the dominant LPAR in the CNS and is highly expressed
in GBM.92 LPA(1–3) are expressed at low levels in the normal
human brain, although their expression is upregulated following
brain injury.92
A study using a microglia co-culture system demonstrated that
GBM secreted factors that increased LPA1 and ATX levels in
microglia, which could be further increased by hypoxia.
Microglial-induced GBM proliferation and migration could be
inhibited through the pharmacological inhibition of LPA1 recep-
tor. Increased levels of LPA1 were also observed in GBM in a
microglia co-culture system compared with other gliomas and
were associated with a poorer survival rate (Fig. 6).93
A preliminary study investigated the effects of the LPAR inhi-
bitor, Ki6425, on the U87 GBM cell line. Given that GPCRs have
a role in hypoxia, the study investigated which LPARs and down-
stream signalling pathways were involved under hypoxic condi-
tions, finding that LPA1 was selective to the U87 cell line. From
these results, the genetic profile of LPARs in the U87 cell line was
investigated using qPCR. The study showed that EGFR was the
main receptor tyrosine kinase (RTK), which was activated under
hypoxic conditions in the U87 cell line. Inhibition of hypoxia-
induced EGFR phosphorylation by the LPAR inhibitor Ki6425
was also observed in the U87 cell line.94
Furthering our understanding of LPA1 antagonists in vitro and
in vivo could lead to the development of new therapeutics, given
that LPARs are potential targets for GBM treatment.
Smoothened receptors
The Smo GPCR is the signal transducer of the Hedgehog (Hh)
pathway and belongs to the F subfamily, frizzled/smoothened
receptors.95 The Hh signalling pathway provides instructional
cues during development that contribute to postdevelopmental
homeostasis and wound healing. Corruption of the Hh pathway
can lead to developmental disorders and cancer.95 Hh proteins
are secreted ligands synthesised in discrete regions. The receptor
of Hh is the multitransmembrane protein Patched (PTCH),
which is expressed in cells close to the source of Hh. Binding
of Hh to PTCH activates Smo, which signals through the tran-
scription factor glioma-associated oncogene-1 (Gli-1) and regu-
lates gene expression.95 Therefore, targeting the Hh pathway
and Smo has become an attractive therapeutic target for treating
GBM.
Currently, there is much interest in Hh signalling pathway
inhibitors as anticancer agents, particularly Smo receptor antag-
onists, resulting in the approval of two drugs: sonidegib and vis-
modegib (Fig. 5).96 Although sonidegib has shown efficacy in
Phase II clinical trials for medulloblastomas, it has not yet been
used in the treatment of GBM.97 Vismodegib is approved for
the treatment of basal cell carcinoma and is an inhibitor of the
Hh pathway that binds to Smo. It underwent a Phase II clinical
trial (ClinicalTrial.gov ID: NCT00980343) for glioma because it
demonstrated antitumour activity.98 No mortality or serious
adverse effects were reported. However, its underlying mecha-
nisms have not yet been investigated in glioma. In 2018, there
were 11 Hh signalling pathway inhibitor compounds in clinical
trials for different cancers, ten of which were Smo antagonists.96
Research has shown that Hh signalling is activated in glioma
grades II and III but it has not been determined whether it is acti-
vated in GBM.43,99
The determination of Smo crystal structures now offers the
possibility to perform computational structure-based screens for
new antagonists.100 By focusing screening on readily available
molecules, hits can be tested quickly, and it also reduces the rate
of false positives. This technique is particularly successful with
GPCR structures for which hit rates are 17–58%.100 For example,
a study identified 21 novel smoothened ligands by using
structure-based docking. A screen for analogues then revealed a
further six compounds, one which was effective against the
D473H mutant of Smo, which contributes to clinical resistance
to vismodegib in cancer treatment.100
Concluding remarks
New therapeutic approaches are desperately needed for the treat-
ment of GBM; thus, here we reviewed recent advances in GPCRs
as potential emerging therapeutic targets for GBM. Although
there is scope to develop new therapeutics by targeting GPCRs,
additional research is needed.
The use of chemokines has been pursued in both in vitro,
in vivo, and in Phase I/II clinical trials (Table 2). Given the com-
plicatedness of the chemokine network, it is unlikely that any
single chemokine or receptor could be a tumour marker effective
enough for a GBM diagnosis. Therefore, a proteomic approach
could be effective in the selection of potential tumour markers
for gliomas. A study using sandwich ELISA and protein expres-
sion in GBM tumoral tissue by means of western blot confirmed
that the proteomic approach was effective and identified the che-
mokine receptor CXCR4.101 There is scope to use chemokine
ligands in the treatment of GBM either by looking at biomarkers
or by using them in conjunction with current therapeutics, as








Interaction with lysophosphatidic acid (LPA) and GBM in a microglia co-
culture system, in which elevated levels of LPA1 were associated with a
worse prognosis.
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Although magnetic resonance imaging (MRI) is regularly used
for GBM imaging, recent studies have explored the detection of
GPCR expression in GBM tissue using labelled peptides/ligands
and positron emission tomography (PET) imaging.102 Targeted
alpha-radionuclide therapy has been used to identify NK-1 recep-
tors.103 The CXCR4 chemokine receptor was targeted by the
diagnostic PET agent [68Ga]Ga-PentixaFor,104 with some result
variability observed compared with immunohistochemical anal-
ysis. It was concluded that, when high CXCR4 expression can be
identified with [68Ga]Ga-PentixaFor, these patients might be
good candidates for targeted radionuclide therapy with [177Lu]
Lu-pentixather.104 CXCR4 expression has also been shown to
increase the intensity of T2-weighted MRI.105 Research has com-
bined PET imaging with MRI to identify dopamine receptors,106
whereas MRI and NIR fluorescence imaging have been used to
identify LPL receptors.107 The ongoing work in this field is high-
lighted in Table 2.
The DRD2 antagonist ONC201 is currently undergoing Phase
II clinical trials and has shown antitumour activity in GBM.67
Pending the successful outcome of the clinical trial, there is huge
potential for this and similar drugs.
The use of cannabinoids as a treatment for GBM has been
explored, either by exploiting the use of CB1 receptor agonists
or antagonists or of CB2 receptor agonists (Table 2). Cannabi-
noids are promising in the treatment of GBM because they target
cancer hallmarks, such as programmed cell death, neoangiogen-
esis, and tissue invasion. A recent receptor crystal structure could
further aid the rational design and development of new com-
pounds in this space.108 Furthermore, the effects of cannabinoids
could be enhanced when used with other chemotherapeutic
agents, although there is a need for further studies using
cannabinoids given that there have only been a few in vitro
and in vivo studies carried out to date.63
Both in vitro and in vivo studies showed a highly synergistic
effect on GBM cells with TMZ and the MC4R antagonist,
ML00253764. A significant decrease in tumour volumes was
observed in vivo.74 It has also been shown that there is a shorter
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express the MC4R rs489693 AA genotype.75 As such, targeting
MC4R is a potential attractive treatment for GBM.
The overexpression of NK-1 is present in a variety of tumours,
including glioma, in which the number of NK-1 receptors
expressed on cells is greater than that observed on normal
human cells and is correlated with the degree of malignancy.109
Use of drug repurposing and/ or combination therapy to target
NK-1 has become an attractive treatment, with work being car-
ried out continuously in this area.
In terms of lesser studied GPCR targets, there are several with
potential for GBM, but requiring further studies. Adhesion recep-
tors are the second largest family of GPCRs. The challenges with
EMR2 and EMR3 receptors are their complex structure with no
mouse orthologues and limited information about their intracel-
lular targets.84 High GPR133 levels are associated with a reduced
patient survival rate and, thus, there is scope for this receptor to
be explored further. Currently, there are no approved drugs on
the market that use aGPCRs as a therapeutic target and, there-
fore, more studies are required to better understand their mech-
anism of action.
LPA antagonists have only been studied in a microglia co-
culture system, but an LPA1 antagonist has shown promise in
the treatment of multiple fibrotic diseases. A further understand-
ing of these receptors and their GBM role is needed to develop
new targeted therapeutics. The final target of interest is the
Smo receptor, because there is great interest in Hh signalling
pathway inhibitors as anticancer agents. Vismodegib was used
as part of a Phase II clinical trial for the treatment of glioma,
but its mechanism has not been investigated fully. Although
Hh signalling is activated in grade II and III gliomas, it is not clear
whether it is activated in GBM. Thus, more studies are needed on
these interesting receptor types.
Treating GBM is challenging because most approved anti-
cancer drugs do not readily cross the BBB and there is the issue
of tumour recurrence, thus limiting the options for treatment.
Given the aggressive and complex nature of GBM, effective treat-
ments that target the CNS are a serious unmet medical need.
Therefore, the identification and validation of drug targets asso-
ciated with GBM disease progression present an exciting oppor-
tunity to improve treatment of this devastating disease.
The introduction of new therapeutic targets for the treatment
of GBM could improve the outlook for patients; however, a sig-
nificant amount of research is required, such as computational
work, which could allow novel ligands to be designed. Currently,
there are no GPCR drugs approved for the treatment of GBM,
with the most established targets being the chemokine, cannabi-
noid and dopamine receptors (Table 2). Future work should also
focus on the adhesion GPCRs, LPAR and Smo receptors to initiate
new drug screening strategies and targeted delivery of therapies
to treat GBM in a safe and efficient manner.
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